Ranbaxy to pay $420,000 for sub-standard drugs

July 09, 2013 12:44 pm | Updated November 17, 2021 05:35 am IST - Washington

Indian drug manufacturer Ranbaxy will pay Idaho state in northwestern US nearly $420,000 to settle civil and criminal complaints of selling drugs of inferior strength, purity or quality.

Idaho had joined several states and the US government in alleging that Ranbaxy products manufactured between April 2003 and September 2010 did not meet US Food and Drug Administration standards and caused Medicaid to pay fraudulent claims. Medicaid is a US health programme for families and individuals with low income and resources.

The alleged 26 sub-standard generic drugs were made at Ranbaxy’s factories in Paonta Sahib and Dewas in India.

The company agreed to a $500 million settlement with the federal and state governments. About $266.7 million of that will go to Medicaid programmes that are jointly funded by federal and state taxes.

“Taxpayers expect their tax dollars to be used to pay for a legitimate service,” Idaho Attorney General Lawrence Wasden said in a press release. “This settlement reflects our resolve to address losses to the Idaho Medicaid programme caused by individuals and companies.”

Idaho’s share of the settlement is $419,914. About half of that will go to Idaho Medicaid as restitution, and about half will go to Idaho’s general fund.

The company also pleaded guilty to seven felony counts of violating the US Food, Drug and Cosmetic Act and agreed to pay $150 million in criminal fines and forfeitures.

Top News Today

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.